This article describes a neuroscience mechanism linking serotonin to cognitive flexibility in OCD, which supports the pharmacological rationale for serotonergic treatments but does not report on drug development, clinical trials, or prescribing guidelines.
The European Medicines Agency has accepted Teva's marketing authorization application for long-acting injectable olanzapine for the treatment of schizophrenia, marking a potential new regulatory milestone for this antipsychotic formulation in the EU.
A study in JAMA Network Open reports that a single dose of psilocybin provided rapid and sustained depression symptom relief for over three months compared to placebo, highlighting the challenge of blinding in psychedelic trials.
This study demonstrates that pre-emptive pharmacogenetic testing influences antidepressant discontinuation rates, providing evidence for the clinical utility of pharmacogenomics in optimizing antidepressant prescribing.
This meta-analysis evaluates the efficacy of combining psychotherapy with antidepressant medication for depression and anxiety disorders, providing evidence for combination treatment strategies.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Oct 29 – May 22)
- Consider the possibility of placebo response or unblinding when interpreting rapid, sustained antidepressant effects in psychedelic trials, as this may conflicate efficacy assessments.
- Utilize pre-emptive pharmacogenetic testing to help reduce antidepressant discontinuation rates and optimize initial prescribing choices.
- Monitor for regulatory updates regarding long-acting injectable olanzapine in the EU, as this new formulation may offer alternative management options for schizophrenia patients.
- Rely on established serotonergic pharmacotherapy for OCD rather than emerging preclinical cannabinoid data, as current evidence supports standard serotonergic mechanisms for cognitive flexibility.
- Prioritize combination therapy with psychotherapy and antidepressants for patients with depression or anxiety disorders to leverage evidence-based synergistic efficacy.
- Recognize that long-acting injectable clozapine is not currently available in the US, limiting depot options for treatment-resistant schizophrenia to oral formulations or other antipsychotics.
- Remain cautious regarding the clinical application of cannabidivarin for schizophrenia negative symptoms, as current data is limited to preclinical rat models and lacks human trial validation.
Policy & Regulation 1
Long-acting injectable formulations of clozapine are not currently available in the United States, distinguishing them from the standard oral formulation used for treatment-resistant schizophrenia.
Drug Development 1
Preclinical data indicate that the phytocannabinoid cannabidivarin alleviates cognitive and social deficits in a schizophrenia-relevant rat model, suggesting potential for treating negative symptoms.